ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the 'Company' / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.
